Section 4 of 6
Clinical evidence
448 evidence topics · 63 sources
Study summaries
VANQUISH-1
Objective
Study objective in the ClinicalTrials.gov record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2025-06-23” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2027-07-01” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-08-01” (opens the source at this quote in a new tab)
“First Posted 2025-08-05” (opens the source at this quote in a new tab)
“Last Update Posted 2025-11-24” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Number of randomizing sites in the baseline poster
Initiation and completion of enrollment
Expected completion and timing of data
Study design
Design, duration, randomization ratio, and stratification
Official title in the ClinicalTrials.gov record
Allocation of fewer participants to the lowest dose
Diversity plan
Extension study after the 78-week treatment period
Eligibility criteria
Key inclusion and exclusion criteria in the design poster
“Adults ≥18 years of age” (opens the source at this quote in a new tab)
“BMI ≥30 kg/m2 or” (opens the source at this quote in a new tab)
“History of diabetes” (opens the source at this quote in a new tab)
“Prior or planned bariatric surgery” (opens the source at this quote in a new tab)
“History of acute or chronic pancreatitis” (opens the source at this quote in a new tab)
“Impaired renal function” (opens the source at this quote in a new tab)
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Treatment arms in the ClinicalTrials.gov record
| Arm | Description in the record |
|---|---|
| Placebo | “VK2735 Placebo Comparator Once Weekly” |
| Dose 1 | “VK2735 7.5mg Once Weekly” |
| Dose 2 | “VK2735 12.5mg Once Weekly” |
| Dose 3 | “VK2735 17.5mg Once Weekly” |
| Intervention | “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly” |
Subcutaneous formulation: dose arms and lifestyle counseling
Subcutaneous formulation: dose titration from 1.25 mg
Subcutaneous formulation: transition from vial and syringe to autoinjector
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary endpoint
Secondary endpoint: categorical weight reduction
Additional outcomes: function, cardiometabolic health, mental health, and work productivity
Regulatory basis for the primary endpoint and for responder analyses
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Enrollment reported after completion
Description of analysis sets
Population analyzed for baseline characteristics
Efficacy and safety analysis sets
No evidence found.
Results
Participant disposition
Blinded discontinuation rate across the VANQUISH program
Baseline characteristics
Demographics and body size compared with NHANES
| Characteristic | VANQUISH-1 (N=4660) | NHANES |
|---|---|---|
| Age, mean (SD), years | “50.4 (13.81)” | “47.6 (13.97)” |
| Age 65 years or older | “17%” | “19%” |
| Sex, female to male | “65%:35%” | “51%:49%” |
| Waist circumference, mean (SD), cm | “116.2 (16.13)” | “109.2 (11.35)” |
| BMI, mean (SD), kg/m2 | “38.3 (7.31)” | “33.7 (5.10)” |
| BMI 27 to less than 30 kg/m2 | “5%” | “33%” |
| BMI 30 to less than 35 kg/m2 | “33%” | “36%” |
| BMI 35 to less than 40 kg/m2 | “28%” | “16%” |
| BMI 40 kg/m2 or higher | “33%” | “15%” |
Baseline comorbidities
Baseline laboratory values
| Measurement, mean (SD) | VANQUISH-1 (N=4660) |
|---|---|
| HbA1c, % | “5.5 (0.40)” |
| Glucose, mg/dL | “97.2 (11.18)” |
| Insulin, µIU/mL | “16.4 (15.66)” |
| Total cholesterol, mg/dL | “192.6 (39.69)” |
| Triglyceride, mg/dL | “126.8 (61.85)” |
| hsCRP, mg/L | “6.0 (8.82)” |
Representativeness stated by the authors
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: limitations evident from the available VANQUISH-1 documents
VANQUISH-1 is ongoing, with primary completion estimated for July 2027 and data expected in the second half of 2027, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, and two congress posters authored by company employees with or without study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.
Reported enrollment differs between documents: the registry lists an estimated 4,500 participants, the enrollment release reported “approximately 4,650 adults”, the baseline poster reported 4,660 participants randomized from 138 sites, and later releases and the investor presentation describe approximately or more than 4,500. The registry lists 137 locations.
The 7.5 mg arm was planned to be smaller than the other arms (816 compared with 1,224 planned participants per arm), so estimates for that dose will be less precise. The trial enrolled participants without diabetes in the United States and Puerto Rico only; 65% of participants were women, and the mean BMI was 38.3 kg/m2, higher than the 33.7 kg/m2 of the NHANES comparison population. Prior use of GLP-1 receptor agonists or dual GLP-1/GIP receptor agonists within 6 months of screening was excluded. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector introduced in the first quarter of 2026. The extension study, which adds every-other-week and monthly regimens, is expected to report in 2028 and will not inform the primary 78-week analysis.
VANQUISH-2
Objective
Study objective in the ClinicalTrials.gov record
Cardiometabolic hypothesis in the congress abstract
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2025-06-23” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2027-07-01” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-08-01” (opens the source at this quote in a new tab)
“First Posted 2025-08-05” (opens the source at this quote in a new tab)
“Last Update Posted 2026-04-07” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Number of randomizing sites in the baseline poster
Expected completion and timing of data
Study design
Design, duration, randomization ratio, and stratification
Official title in the ClinicalTrials.gov record
Allocation of fewer participants to the lowest dose
Extension study after the 78-week treatment period
Eligibility criteria
Key inclusion and exclusion criteria in the design poster
“Adults ≥18 years of age” (opens the source at this quote in a new tab)
“BMI ≥27 kg/m2” (opens the source at this quote in a new tab)
“Prior or planned bariatric surgery” (opens the source at this quote in a new tab)
“History of acute or chronic pancreatitis” (opens the source at this quote in a new tab)
Key criteria in the congress abstract
Inclusion criteria and permitted background glucose-lowering therapy in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Treatment arms in the ClinicalTrials.gov record
| Arm | Description in the record |
|---|---|
| Placebo | “VK2735 Placebo Comparator Once Weekly” |
| Dose 1 | “VK2735 7.5mg Once Weekly” |
| Dose 2 | “VK2735 12.5mg Once Weekly” |
| Dose 3 | “VK2735 17.5mg Once Weekly” |
| Intervention | “VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly” |
Subcutaneous formulation: dose arms, time at target dose, and lifestyle counseling
Subcutaneous formulation: dose titration from 1.25 mg
Subcutaneous formulation: transition from vial and syringe to autoinjector
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary endpoint
Secondary endpoint: categorical weight reduction
Glycemic and cardiometabolic outcomes and adjudicated safety events
Additional outcomes: function, cardiometabolic health, mental health, and work productivity
Rationale stated in the design poster and the baseline poster
Regulatory basis for the primary endpoint and for glycemic secondary endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Randomized participants per arm in the baseline poster
| Arm | Randomized participants |
|---|---|
| Placebo | “N=276” |
| VK2735 7.5 mg | “N=185” |
| VK2735 12.5 mg | “N=276” |
| VK2735 17.5 mg | “N=276” |
| Total | “1013 participants were randomized from 127 U.S. study sites” |
Enrollment reported after completion
Description of analysis sets
Population analyzed for baseline characteristics
Efficacy and safety analysis sets
No evidence found.
Results
Participant disposition
Blinded discontinuation rate across the VANQUISH program
Baseline characteristics
Demographics and body size compared with NHANES
| Characteristic | VANQUISH-2 (N=1013) | NHANES |
|---|---|---|
| Age, mean (SD), years | “58.3 (11.5)” | “59.51 (11.7)” |
| Age 65 years or older | “31%” | “38%” |
| Sex, female to male, % | “49:51” | “49:51” |
| Weight, mean (SD), kg | “105.3 (23.5)” | “99.8 (20.2)” |
| Waist circumference, mean (SD), cm | “118.2 (15.8)” | “116.4 (12.6)” |
| BMI, mean (SD), kg/m2 | “37.1 (7.1)” | “35.7 (6.2)” |
| BMI 27 to less than 30 kg/m2 | “13%” | “22%” |
| BMI 30 to less than 35 kg/m2 | “32%” | “34%” |
| BMI 35 to less than 40 kg/m2 | “26%” | “22%” |
| BMI 40 kg/m2 or higher | “29%” | “22%” |
Race and ethnicity, prior GLP-1 receptor agonist exposure, and diabetes duration
Representativeness stated by the authors
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: limitations evident from the available VANQUISH-2 documents
VANQUISH-2 is ongoing, with primary completion estimated for July 2027, data expected in the second half of 2027, and readout expected after VANQUISH-1, so no efficacy, patient-reported outcome, or safety result is available. All available information comes from the ClinicalTrials.gov record, company press releases, an investor presentation, company call and conference transcripts, a congress abstract and poster authored by company employees, and a baseline poster authored by company employees and study investigators; no peer-reviewed design or results publication was identified, and the ClinicalTrials.gov record has posted no results.
Enrollment fell short of the plan: the design poster planned approximately 1,122 participants (306 per arm and 204 in the 7.5 mg arm) and the initiation release targeted approximately 1100, while 1,013 participants were randomized (276 per arm and 185 in the 7.5 mg arm).
The 7.5 mg arm is the smallest, so estimates for that dose will be less precise. The trial enrolled adults with type 2 diabetes and HbA1c of 7% to 11% in the United States and Puerto Rico only; background therapy with DPP-4 inhibitors, amylin analogues, GLP-1 receptor agonists, and dual GLP-1/GIP receptor agonists was not permitted, while 21% of participants reported prior GLP-1 receptor agonist exposure. Participants had a mean BMI of 37.1 kg/m2 and a mean diabetes duration of 10.3 years, and the prevalence of obesity complications was lower than in the NHANES comparison population. The company describes the blinded discontinuation rate only qualitatively. The device changed during the trial, from vial and syringe to an autoinjector, and in July 2026 the company stated that “almost everybody” in VANQUISH-2 was using the autoinjector. The extension study is expected to report in 2028 and will not inform the primary 78-week analysis.
SUNRISE-1
Objective
Registry objective: oral VK2735 in adults without type 2 diabetes
Company-stated objective of the SUNRISE program
Location and study date
Company-reported initiation and enrollment status
Study sites shared with the VANQUISH program
Planned start date before initiation
Study design
Randomized, double-blind, placebo-controlled, parallel-arm design
Treatment period, screening, and follow-up
Program structure modeled on the VANQUISH program
FDA end-of-phase 2 meeting for the oral tablet
Eligibility criteria
Inclusion criteria
Company description of the enrolled population
Treatment
Registry arms: doses described as dose levels
“VK2735 Dose level 1 orally once daily” (opens the source at this quote in a new tab)
“VK2735 Dose level 2 orally once daily” (opens the source at this quote in a new tab)
“VK2735 Dose level 3 orally once daily” (opens the source at this quote in a new tab)
“Placebo comparator orally once daily” (opens the source at this quote in a new tab)
Company-stated doses: 27.5 mg, 35 mg, and 55 mg once daily
Dose titration schedule
Rationale for the selected doses: tablet burden and cost of goods
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary endpoint: percent change in body weight at week 68
Secondary and exploratory endpoints
FDA draft guidance: primary efficacy endpoint for weight-reduction drugs
FDA draft guidance: weight reduction indication spans at least one year
Statistical analysis description
Number of participants (Planned and analyzed)
Basis for the reduced sample size: reuse of subcutaneous safety data
Description of analysis sets
Superiority hypothesis for the primary endpoint
Analysis populations
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
SUNRISE-1 had reported no results as of November 2026, and every leaf on disposition, baseline characteristics, efficacy, quality of life, and safety is empty. The design is known only from the ClinicalTrials.gov record, company press releases, an investor presentation, and transcripts of investor calls; no protocol, statistical analysis plan, or peer-reviewed design paper is available.
The registry and the company documents differ on status and on doses. The company announced the program's initiation on October 14, 2026, and its later documents describe the trials as “Underway”, while the registry record still lists the study as “Not yet recruiting” with an estimated start in November 2026. The registry describes the three active arms only as dose levels 1 to 3; the doses of 27.5 mg, 35 mg, and 55 mg are stated in company releases.
The registry record lists one primary outcome and no secondary outcomes, so the responder endpoints and exploratory endpoints (function, metabolic health, mental health, productivity) rest on company documents. The planned enrollment of 560 participants is about 75% smaller than the subcutaneous phase 3 program, a reduction the company attributes to reusing safety data from the subcutaneous trials, which the FDA accepted while noting “risks going from phase II to phase III”. The company states that the doses were chosen in part to lower “the tablet burden” and for gross margin, and gives no exposure-response analysis for them. The FDA's details from the end-of-phase 2 meeting are not public, and the company declined to describe them.
SUNRISE-2
Objective
Registry objective: oral VK2735 in adults with type 2 diabetes
Company-stated objective of the SUNRISE program
Location and study date
Company-reported initiation and enrollment status
Study sites shared with the VANQUISH program
Planned start date before initiation
Study design
Randomized, double-blind, placebo-controlled, parallel-arm design
Treatment period, screening, and follow-up
Separate trial in type 2 diabetes, modeled on the VANQUISH program
FDA draft guidance: trials enrolling only participants with diabetes
FDA end-of-phase 2 meeting for the oral tablet
Eligibility criteria
Inclusion criteria: body mass index and type 2 diabetes
Exclusion criteria: diabetes-related
Exclusion criteria: other
Company description of the enrolled population
Treatment
Registry arms: doses described as dose levels
“VK2735 Dose level 1 orally once daily” (opens the source at this quote in a new tab)
“VK2735 Dose level 2 orally once daily” (opens the source at this quote in a new tab)
“VK2735 Dose level 3 orally once daily” (opens the source at this quote in a new tab)
“Placebo comparator orally once daily” (opens the source at this quote in a new tab)
Company-stated doses: 27.5 mg, 35 mg, and 55 mg once daily
Dose titration schedule
Rationale for the selected doses: tablet burden and cost of goods
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary endpoint: percent change in body weight at week 68
Secondary and exploratory endpoints
FDA draft guidance: primary efficacy endpoint for weight-reduction drugs
FDA draft guidance: weight reduction indication spans at least one year
Statistical analysis description
Number of participants (Planned and analyzed)
Basis for the reduced sample size: reuse of subcutaneous safety data
Description of analysis sets
Superiority hypothesis for the primary endpoint
Analysis populations
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
SUNRISE-2 had reported no results as of November 2026, and every leaf on disposition, baseline characteristics, efficacy, quality of life, and safety is empty. The design is known only from the ClinicalTrials.gov record, company press releases, an investor presentation, and transcripts of investor calls; no protocol, statistical analysis plan, or peer-reviewed design paper is available.
The registry and the company documents differ on status, doses, and population. The company announced the program's initiation on October 14, 2026, and its later documents describe the trials as “Underway”, while the registry record still lists the study as “Not yet recruiting” with an estimated start in November 2026. The registry describes the three active arms only as dose levels 1 to 3; the doses of 27.5 mg, 35 mg, and 55 mg are stated in company releases. The company describes participants as “obese or overweight”, while the registry's inclusion criteria are a body mass index of 27 kg/m2 or more with type 2 diabetes and an HbA1c of 7% to 11%.
The registry record lists one primary outcome and no secondary outcomes, so the responder endpoints and the exploratory endpoints rest on company documents, and neither source names HbA1c as an outcome. Participants treated with GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists, DPP-4 inhibitors, or amylin analogues are excluded, and the registry names diet, exercise, and oral glucose-lowering agents as permitted background therapy. The planned enrollment of 560 participants per trial is about 75% smaller than the subcutaneous phase 3 program, a reduction the company attributes to reusing safety data from the subcutaneous trials, which the FDA accepted while noting “risks going from phase II to phase III”. The company states that the doses were chosen in part to lower “the tablet burden” and for gross margin. The FDA's details from the end-of-phase 2 meeting are not public, and the company declined to describe them. Primary completion is estimated 3 months later than for SUNRISE-1 (October 2028 against July 2028).
VENTURE
Objective
Dose finding for weight loss over 13 weeks to inform phase 3
“This study aimed to determine doses of VK2735, a novel glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide (GLP‐1/GIP) receptor dual agonist, that are effective for weight loss over 13 weeks of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The VENTURE study was a 13‐week, dose‐ranging study designed to provide preliminary efficacy and safety data for subcutaneous VK2735 as a treatment for obesity to inform phase 3 study design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main objectives of the VENTURE study were to evaluate the safety, tolerability, and weight loss efficacy of VK2735.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered objectives: safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics
Location and study date
Twenty sites in the United States, August 2023 to February 2024
“VENTURE was a phase 2, 13‐week, randomized, double‐blind, placebo‐controlled, parallel‐arm, dose‐finding study conducted in 20 sites in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The trial was conducted between August 31, 2023, and February 23, 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered study dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2023-08-31” |
| Primary completion (actual) | “2024-02-27” |
| Study completion (actual) | “2024-04-02” |
Topline results announced in February 2024
Study design
Randomized, double-blind, placebo-controlled, parallel-arm, dose-ranging design
“VENTURE was a phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study of weekly subcutaneous VK2735 in adults with obesity or overweight and ≥ 1 weight‐related comorbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The total study duration was 23 weeks, comprising a 4‐week screening period, a 13‐week treatment period, and an approximately 6‐week safety follow‐up period (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central randomization and blinding
“All participants were centrally assigned to a randomized study intervention using an Interactive Web Response System (IWRS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Once deemed eligible for enrollment in the study, participants were assigned a sequential randomization number prior to first dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The investigators and study staff were blinded to each participant's assigned study intervention throughout the course of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subcutaneous injections were matched for volume for placebo and active treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered design and masking
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Triple” |
Eligibility criteria
Adults with obesity, or overweight with a weight-related comorbidity, without diabetes
“Eligible participants were over the age of 18 years, with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 and at least one weight‐related comorbid condition (treated or untreated).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight‐related comorbid conditions include hypertension, dyslipidemia, obstructive sleep apnea, and cardiovascular disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants with BMI > 50 kg/m2 or with certain medical conditions, including diabetes, were not eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered inclusion criteria
Registered exclusion criteria: diabetes, pancreatitis, calcitonin, and prior incretin or weight-loss drugs
Treatment
Four weekly subcutaneous doses or matched placebo, randomized 1:1:1:1:1
“Participants who met eligibility criteria were randomized to one of four VK2735 weekly subcutaneous injection treatment groups (2.5, 5.0, 10, or 15 mg) or the matched placebo injection group in a 1:1:1:1:1 ratio on day 1 (Figure S1 and Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Placebo injections were matched for volume.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Titration to final dose was conducted as shown in Figure S1 for the active treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fasting was not otherwise required for dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Titration schedule to the final dose in each arm
| Dose arm | Titration schedule |
|---|---|
| VK2735 2.5 mg | “2.5 mg cohort = 2.5 x 13 weeks” |
| VK2735 5 mg | “5 mg cohort = 2.5 mg x 3 wks, 5 mg x 10 wks” |
| VK2735 10 mg | “10 mg cohort = 2.5 mg x 3 wks, 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 4 wks” |
| VK2735 15 mg | “15 mg cohort = 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 3 wks, 15 mg x 4 wks” |
Starting dose of 5.0 mg in the 15 mg arm
Background diet and exercise counseling in all arms
“All participants were encouraged to exercise for approximately 150 min per week and reduce daily intake by 500 kcal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Instructional materials were provided at Week 0 (i.e., randomization), and counseling sessions were conducted at study sites at Week 3, Week 6, and Week 9 (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered intervention description
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary, secondary, and exploratory efficacy endpoints
“The primary endpoint was percent (relative) change from baseline to Week 13 in body weight.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary efficacy endpoints were observed and change from baseline to Week 13 in body weight and the proportion of participants losing ≥ 5% and 10% of baseline weight at Week 13.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of participants losing ≥ 15% of baseline weight was an exploratory objective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety endpoints
“Safety endpoints included incidence of treatment‐emergent adverse events (TEAEs), treatment‐emergent serious adverse events (TESAEs), and adverse events of special interest.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Changes in vital signs and the proportion of participants with anti‐drug antibodies were also evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory glycemic, cardiometabolic, and anthropometric endpoints
“Key exploratory endpoints included effects of VK2735 on glycemic status, cardiometabolic parameters, and anthropometric parameters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Categories of glycemic control were defined by fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) as: normoglycemic = FPG < 100 mg/dL and HbA1c < 5.7%, prediabetes = FPG 100–125 mg/dL or HbA1c 5.7%–6.4%, and diabetes = FPG > 125 mg/dL or HbA1c > 6.4%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic syndrome definition used in the exploratory analysis
Registered outcome measures
Weight reduction and its association with morbidity, mortality, and health care spending
“Interventional and epidemiological studies support that reduction of excess body weight reduces morbidity and mortality, and that this reduction is correlated with the magnitude of weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight loss of as little as 5%–10% is associated with a reduction in new onset type 2 diabetes and some cancers and improvements in sleep apnea, hypertension, dyslipidemia, hyperglycemia, osteoarthritis of the knee, and polycystic ovary disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following a 5% reduction of body mass index (BMI), measured as weight in kilograms divided by height in meters squared (kg/m2), adults with a baseline BMI of 30 kg/m2 are estimated to spend 7% less on health care, with the magnitude of benefit correlating to the magnitude of weight reduction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory primary endpoint for weight-reduction drugs
Categorical responder endpoints: regulatory caution
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation
“Sample size of 29 in active and placebo groups was estimated to achieve 84% power to reject the null hypothesis of equal means when the population mean difference (percent change from baseline) between treatment groups is 2.6% with standard deviations (SD) of 3.3% for each treatment group with a significance level (alpha) of 0.05 using a two‐sided, two‐sample t‐test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants randomized and analyzed
“In total, 176 participants were randomized into the study, with approximately 35 participants randomized to placebo or each active treatment group (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety population (N = 175) excludes one participant in the 10 mg group who did not receive treatment and the mITT population used for efficacy analyses (N = 174) excludes that participant and one participant in the placebo group who did not have an evaluable post‐baseline assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Randomized, modified intent-to-treat, and safety populations
“The randomized population includes all participants who were randomized into the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The modified intent‐to‐treat (mITT) population is defined as all participants within the ITT population who had at least one baseline and post‐baseline body weight assessment and received at least one dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety population is defined as all randomized participants who received at least one dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic subset used for the off-treatment follow-up analysis
Mixed model for repeated measures for the primary endpoint
“Percent change from baseline was analyzed using a mixed model for repeated measures (MMRM) approach with baseline treatment, visit, and treatment*visit interaction as factors and baseline weight as a covariate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If there were multiple weights on a particular day, the average of measurements on that day was used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Handling of data after treatment discontinuation and missing data
“Prior to performing the model, any assessments taken after treatment discontinuation +9 days were set to missing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MMRM model used a likelihood‐based approach to manage missing data, assuming data were missing completely at random or missing at random.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiplicity control and supportive analyses
“All tests were two‐sided and conducted at a significance level of 0.05.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A step‐down closed testing procedure was utilized to preserve the family‐wise type I error at 0.05 and each dose group was tested versus placebo in the following order: VK2735 15, 10, 5, and 2.5 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A nonparametric Wilcoxon rank sum test was also used as a supportive analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Logistic regression for categorical weight-reduction endpoints
Exploratory shift analyses: observed values without imputation
Post hoc predicted cardiovascular risk model
Results
Participant disposition
Study completion and reasons for early study discontinuation
“Overall, 167 of the 176 randomized participants (95%) completed the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The reasons for early study discontinuation were AEs (n = 3), withdrawal by participant (n = 3), loss to follow‐up (n = 2), and death (n = 1; Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 24 of 176 participants (14%) discontinued the treatment early (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common reason for early treatment discontinuation was AEs (15/176 participants [8.5%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients could discontinue treatment and remain in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early treatment and study discontinuation by dose arm, safety population
| Measure, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Discontinued treatment early | “5 (14)”View highlighted excerpt for this quote | “2 (6)”View highlighted excerpt for this quote | “4 (11)”View highlighted excerpt for this quote | “5 (14)”View highlighted excerpt for this quote | “7 (20)”View highlighted excerpt for this quote |
| Discontinued study early | “2 (6)”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “2 (6)”View highlighted excerpt for this quote | “2 (6)”View highlighted excerpt for this quote |
Discontinuation as reported in the topline release
Baseline characteristics
Demographic and clinical characteristics by dose arm, randomized population
“Groups were well matched for baseline characteristics in the randomized population (Table 1), with no significant differences between groups for any parameter.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of participants were non‐Hispanic, White, and female, and the mean age was approximately 50 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic syndrome at baseline by dose arm
| Arm | MetS at baseline, n/N (%) |
|---|---|
| Placebo | “18/34 (53)” |
| VK2735 2.5 mg | “21/35 (60)” |
| VK2735 5.0 mg | “22/35 (63)” |
| VK2735 10 mg | “14/35 (40)” |
| VK2735 15 mg | “13/35 (37)” |
| All VK2735 | “70/140 (50)” |
Baseline cardiovascular risk factors in the cardiovascular risk analysis subset
| Characteristic | Placebo (n=27) | All VK2735 (n=116) |
|---|---|---|
| Age, years, mean (SD) | “51.9 (12.2)” | “51.8 (12.1)” |
| Class 3 obesity, BMI 40 or higher, n (%) | “13 (48.2)” | “27 (23.3)” |
| Current smoker, n (%) | “2 (7.4)” | “15 (12.9)” |
| Current statin user, n (%) | “5 (18.5)” | “30 (25.9)” |
| Current hypertension medication user, n (%) | “12 (44.4)” | “40 (34.5)” |
Efficacy results
Primary endpoint: percent change in body weight at week 13 by dose, mITT population
“Statistically significant differences in the primary outcome of percent change of weight from baseline to Week 13 were observed for all active treatment groups (−9.1% to −14.7%, vs. −1.7% for placebo) in the mITT population (Table 2, Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results from the Wilcoxon rank sum test were consistent with the primary efficacy analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A dose response was observed for all efficacy measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoint: change in body weight in kilograms at week 13 by dose
| Measure | Placebo (n = 34) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Change from baseline, kg, LS mean (95% CI) | “−1.8 (−3.09, −0.44)”View highlighted excerpt for this quote | “−9.2 (−10.46, −7.86)”View highlighted excerpt for this quote | “−10.7 (−11.97, −9.33)”View highlighted excerpt for this quote | “−13.3 (−14.61, −11.94)”View highlighted excerpt for this quote | “−14.6 (−15.96, −13.30)”View highlighted excerpt for this quote |
| LS mean difference from placebo, kg (95% CI) | Not applicable | “−7.40 (−9.26, −5.54)”View highlighted excerpt for this quote | “−8.88 (−10.76, −7.01)”View highlighted excerpt for this quote | “−11.51 (−13.39, −9.63)”View highlighted excerpt for this quote | “−12.86 (−14.74, −10.99)”View highlighted excerpt for this quote |
Categorical weight reduction of at least 5%, 10%, and 15% at week 13 by dose
“In the active treatment groups, 93% (130/140) of participants had a ≥ 5% weight reduction, compared with 12% (4/34) of participants with placebo treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A dose response was seen at the ≥ 10% weight loss threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The highest two doses (10 and 15 mg) resulted in the largest percentage of patients with a ≥ 15% decrease in body weight.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Topline release: placebo-adjusted weight change and 10% responders by dose
Weight-loss trajectory: separation from placebo at week 1 and no plateau at week 13
Off-treatment follow-up: weight loss persisting 4 and 7 weeks after the last dose
“In the subset of participants who had post‐dose follow‐up visits, persistent weight loss was seen at 4‐ and 7‐week follow‐up visits (Weeks 16 and 19, respectively), shown in Figure 2B.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics in the follow-up subset
Glycemic status: shift from prediabetes to normoglycemia and change in glucose and HbA1c
“Of the 74 participants who had prediabetes at baseline, 58 (78%) shifted to normoglycemic at Week 13 in the active treatment groups and none shifted from prediabetes to diabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Metabolic syndrome resolution at week 13, exploratory analysis
| Measure | Placebo | 2.5 mg | 5 mg | 10 mg | 15 mg | Combined VK2735 arms |
|---|---|---|---|---|---|---|
| MetS at baseline, n | “16” | “21” | “21” | “13” | “10” | “65” |
| Shifting to no MetS at week 13, n (%) | “6 (38 %)” | “14 (67 %)” | “14 (67 %)” | “10 (77 %)” | “6 (60 %)” | “44 (68 %)” |
| p value vs placebo | Not applicable | “0.1102” | “0.0217” | “0.0182” | “0.3892” | “0.0244” |
Blood pressure change at week 13 by dose
Lipids and high-sensitivity C-reactive protein at week 13
“Lipid markers generally declined over the 13‐week study in the active treatment group (N = 141).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only total cholesterol had a p value less than 0.05 versus placebo (p = 0.0396) in this time frame.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| hsCRP, mg/L | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Baseline, median | “4.50”View highlighted excerpt for this quote | “3.50”View highlighted excerpt for this quote | “4.00”View highlighted excerpt for this quote | “3.40”View highlighted excerpt for this quote | “3.70”View highlighted excerpt for this quote |
| Change from baseline, median | “0.20”View highlighted excerpt for this quote | “0.10”View highlighted excerpt for this quote | “−0.30”View highlighted excerpt for this quote | “−0.10”View highlighted excerpt for this quote | “−0.75”View highlighted excerpt for this quote |
Lipids and other cardiometabolic parameters, combined VK2735 arms versus placebo
| Parameter | Mean difference, VK2735 compared with placebo | Standardized mean difference (95% CI) |
|---|---|---|
| Total cholesterol, mg/dL | “–8.03” | “–0.26 (–0.75, 0.22)” |
| Triglycerides, mg/dL | “–11.90” | “–0.22 (–0.70, 0.27)” |
| LDL, mg/dL | “–3.98” | “–0.14 (–0.63, 0.34)” |
| HbA1c, % | “–0.32” | “–1.49 (–2.01, –0.97)” |
| BMI, kg/m² | “–3.52” | “–2.32 (–2.90, –1.75)” |
| SBP, mmHg | “–2.40” | “–0.20 (–0.69, 0.28)” |
Predicted 10-year cardiovascular risk at week 13, post hoc analysis
| Predicted 10-year risk | LS mean difference in percent change from baseline, VK2735 vs placebo (95% CI) | P value |
|---|---|---|
| Cardiovascular disease | “–4.14 (–17.22, 8.94)” | “.532” |
| Atherosclerotic cardiovascular disease | “–6.67 (–19.44, 6.09)” | “.303” |
| Heart failure | “–16.21 (–27.37, –5.06)” | “.005” |
BMI category shifts from baseline to week 13, exploratory analysis
| Baseline category and transition | VK2735 combined | Placebo |
|---|---|---|
| Class III obesity at baseline, n | “n=35” | “n=15” |
| Class III, transitioning to Class II | “57 %” | “13 %” |
| Class III, transitioning to Class I | “11 %” | “0 %” |
| Class III, no change in obesity class | “31 %” | “87 %” |
| Class II obesity at baseline, n | “n=51” | “n=10” |
| Class II, transitioning to Class I | “80 %” | “20 %” |
| Class II, transitioning to overweight | “2 %” | “0 %” |
| Class II, no change in obesity class | “18 %” | “80 %” |
| Class I obesity at baseline, n | “n=46” | “n=8” |
| Class I, transitioning to overweight | “65 %” | “12 %” |
| Class I, transitioning to normal weight | “9 %” | “0 %” |
| Class I, no change in obesity class | “26 %” | “75%” |
| Overweight at baseline, n | “n=8” | “n=1” |
| Overweight, transitioning to normal weight | “50 %” | “0 %” |
Cardiometabolic markers by BMI category change among VK2735-treated participants
| Marker, mean (SD) | Baseline (N=124) | Change with at least one BMI category improvement (N=89) | Change with no BMI category change (N=35) |
|---|---|---|---|
| Hemoglobin A1C, % | “5.49 (0.36)” | “-0.34 (0.25)” | “-0.25 (0.17)” |
| Glucose, mg/dL | “99.8 (8.77)” | “-12.4 (9.69)” | “-10.1 (8.56)” |
| Triglycerides, mg/dL | “122.1 (62.16)” | “-20.1 (56.76)” | “-2.2 (52.40)” |
| Waist circumference, cm | “112.7 (11.34)” | “-10.1 (5.90)” | “-7.7 (4.24)” |
| Systolic blood pressure, mmHg | “124.5 (14.53)” | “-9.0 (12.26)” | “-6.0 (13.47)” |
| Diastolic blood pressure, mmHg | “80.1 (8.69)” | “-4.2 (8.27)” | “-2.8 (8.97)” |
| LDL cholesterol, mg/dL | “116.7 (33.12)” | “-12.3 (27.61)” | “-6.9 (23.45)” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Overall treatment-emergent adverse events and severity
“Of the 175 participants in the safety population, 142 (81.1%) experienced at least one TEAE of any type, and 120 of 175 (68.6%) experienced a total of 356 drug‐related TEAEs (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most drug‐related TEAEs were mild or moderate; 71 of 175 participants (40.6%) experienced a maximum severity of grade 1 (mild), 41 (23.4%) grade 2 (moderate), 8 (4.6%) grade 3 (severe), and no participants experienced grade 4 (life‐threatening) AEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common study drug‐related TEAEs were nausea (64/175 participants [36.6%]), constipation (37/175 [21.1%]), and vomiting (22/175 [12.6%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuation due to adverse events by dose
“In total, 16 of 175 participants (9.1%) experienced at least one TEAE leading to withdrawal of the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common TEAEs experienced by these participants were nausea (five participants), vomiting (four participants), diarrhea (two participants), and headache (two participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No other AEs were experienced by more than one participant who discontinued treatment due to TEAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Event, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| TEAE leading to treatment discontinuation | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “4 (11)”View highlighted excerpt for this quote | “4 (11)”View highlighted excerpt for this quote | “7 (20)”View highlighted excerpt for this quote |
| TEAE leading to study discontinuation | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote |
| Drug-related TEAE leading to study discontinuation | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote |
Gastrointestinal adverse events by dose, all causality
Drug-related gastrointestinal adverse events by severity and dose
“The majority of GI‐related TEAEs were mild or moderate in severity and no grade 4 or 5 TEAEs were observed (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nausea was the most common GI TEAE and had the highest severity (Tables 3 and 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time course of gastrointestinal adverse events
“GI AEs were generally observed early in the study and subsided over time (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dose‐dependent increase in GI TEAEs was observed after initial dosing (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given that the 5 mg dose had a higher GI TEAE rate than the 10 mg dose, there does not seem to be a dose‐dependent increase in GI TEAEs if a 2.5 mg starting dose is used at the beginning of the titration phase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Topline release summary of gastrointestinal tolerability
Serious adverse events and death
“A total of 8 of 175 participants (4.6%) experienced a total of 12 TESAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ten of the twelve TESAEs were considered unrelated to the study drug by investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant in the 5.0 mg dose group experienced two drug‐related TESAEs, atrial fibrillation (possibly related) and dehydration (probably related), which led to study discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One (0.6%) participant died during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“head trauma from a fall” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with underlying causes of hypertension and hyperlipidemia, and it was assessed as not related to the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events of special interest: pancreatitis, gallbladder events, and injection site reactions
“A total of 27 TEAEs of special interest, injection site reaction being the most common, were experienced by 21 of 175 participants (12.0%; Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gallbladder associated AEs of special interest were cholecystitis and cholelithiasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Event of special interest, n (%) | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 35) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Pancreatitis | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Gallbladder associated events | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “1 (3)”View highlighted excerpt for this quote |
| Injection site reactions | “3 (9)”View highlighted excerpt for this quote | “2 (6)”View highlighted excerpt for this quote | “5 (14)”View highlighted excerpt for this quote | “5 (14)”View highlighted excerpt for this quote | “4 (11)”View highlighted excerpt for this quote |
Anti-drug antibodies at week 13
“At Week 13, anti‐drug antibodies were detected in between 9% (2.5 mg group) and 23% (10 mg group) of participants in any treatment group (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Measure | 2.5 mg | 5.0 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Anti-VK2735 antibody positive at week 13, n/N (%) | “3/34 (9)”View highlighted excerpt for this quote | “4/34 (12)”View highlighted excerpt for this quote | “8/35 (23)”View highlighted excerpt for this quote | “5/32 (16)”View highlighted excerpt for this quote |
Heart rate change at week 13 by dose
| Heart rate, bpm | Placebo (n = 35) | 2.5 mg (n = 35) | 5.0 mg (n = 35) | 10 mg (n = 36) | 15 mg (n = 35) |
|---|---|---|---|---|---|
| Baseline, mean (SD) | “74.2 (11.01)”View highlighted excerpt for this quote | “69.9 (10.46)”View highlighted excerpt for this quote | “70.2 (10.45)”View highlighted excerpt for this quote | “71.7 (8.53)”View highlighted excerpt for this quote | “69.3 (9.94)”View highlighted excerpt for this quote |
| Change from baseline, mean (SD) | “1.4 (12.15)”View highlighted excerpt for this quote | “3.3 (11.94)”View highlighted excerpt for this quote | “6.1 (9.33)”View highlighted excerpt for this quote | “9.3 (8.51)”View highlighted excerpt for this quote | “6.9 (8.43)”View highlighted excerpt for this quote |
Heart rate and blood pressure as reported on the 2024 congress poster
| Vital sign | Placebo | 2.5 mg | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|---|
| Heart rate, bpm, baseline | “65.7” | “63.5” | “66.9” | “64.3” | “63.9” |
| Heart rate, bpm, mean change at week 13 | “4.4” | “3.8” | “5.0” | “10.8” | “7.1” |
| Systolic blood pressure, mmHg, mean change at week 13 | “-4.4” | “-7.4” | “-8.8” | “-5.4” | “-9.6” |
| Diastolic blood pressure, mmHg, mean change at week 13 | “-2.2” | “-3.7” | “-5.5” | “-1.5” | “-4.3” |
Other selected adverse events by dose: hypotension, dizziness, fatigue, lipase, and hyperthyroidism
Study limitations
Summary: limitations of the VENTURE evidence
VENTURE was a phase 2 dose-finding trial of 13 weeks of treatment in 176 randomized participants, about 35 per arm, conducted at 20 United States sites. The authors state that it was “limited in size and duration” and “not powered to determine statistical significance for differences between treatment groups for most parameters.” The sample size calculation of 29 participants per arm was based on a two-sample t-test. A 13-week result does not address the FDA draft guidance benchmark, which assesses effectiveness after 1 year of treatment at the maintenance dosage. The topline release reported no weight-loss plateau at week 13, and the authors state that “Maximal therapeutic levels were likely not yet achieved in this limited duration study.”
People with diabetes were excluded, BMI above 50 kg/m2 was excluded, and the randomized population was mostly female and White, with between 65.7% and 82.9% female and between 72.2% and 88.6% White participants per arm. The 15 mg arm started at 5.0 mg while the other arms started at 2.5 mg, and the authors state that the “titration schedule and dosing, will be changed to optimize tolerability in future studies.”
The primary analysis was a mixed model for repeated measures in the modified intent-to-treat population (174 participants), with assessments more than 9 days after treatment discontinuation set to missing and data assumed missing at random. This corresponds to an on-treatment estimand; no treatment-policy analysis that retains off-treatment weights was reported. Off-treatment weight data at weeks 16 and 19 were reported only for a pharmacokinetic subset of 75 participants (63 VK2735, 12 placebo). Responder analyses, which the FDA draft guidance states may “inappropriately exaggerate treatment effects”, were secondary endpoints.
Reported figures differ between documents. The topline release reported 23 participants (13%) discontinuing treatment and 10% responder proportions of 4%, 39%, 62%, 70%, and 88%, while the publication reported 24 of 176 (14%) and 3.0%, 40.1%, 65.1%, 70.4%, and 89.1%. Baseline heart rate on the 2024 poster (63.5 to 66.9 bpm) differs from the publication (69.3 to 74.2 bpm), as does the week 13 heart rate change (3.8 to 10.8 bpm versus 3.3 to 9.3 bpm in active arms). Mean heart rate increased by up to 9.3 bpm in the 10 mg arm versus 1.4 bpm with placebo in the publication. Treatment discontinuation due to adverse events rose with dose, from 1 of 35 (3%) at 2.5 mg to 7 of 35 (20%) at 15 mg, with none on placebo.
The metabolic syndrome, BMI category, and predicted cardiovascular risk analyses were exploratory or post hoc, reported in company releases and congress posters without peer review, used observed values without imputation, and reported no adjustment for multiplicity. The cardiovascular risk subset comprised 143 participants, of whom 110 (20 placebo, 90 VK2735) entered the risk model, and all authors of that poster are company employees. No health-related quality of life or patient-reported outcome was reported. The trial was funded by Viking Therapeutics, and every author of the publication was a site investigator or a company employee. No results are posted on ClinicalTrials.gov.
VENTURE-Oral dosing
Objective
Registry statement of the study aims
Purpose of the exploratory maintenance cohort
Location and study date
Registry study dates
| Milestone | Registry entry |
|---|---|
| Study start (actual) | “2024-12-18” |
| Primary completion (actual) | “2025-06-24” |
| Study completion (actual) | “2025-08-15” |
| First posted | “2025-02-14” |
| Last update posted | “2025-10-06” |
Study sites in the United States
| Site | City | State |
|---|---|---|
| Site 111 | “Peoria” | “Arizona” |
| Site 105 | “Lake Forest” | “California” |
| Site 101 | “Clearwater” | “Florida” |
| Site 108 | “Largo” | “Florida” |
| Site 107 | “Ocoee” | “Florida” |
| Site 102 | “Port Orange” | “Florida” |
| Site 100 | “Indianapolis” | “Indiana” |
| Site 110 | “Louisville” | “Kentucky” |
| Site 114 | “Marrero” | “Louisiana” |
| Site 109 | “City of Saint Peters” | “Missouri” |
| Site 112 | “Kansas City” | “Missouri” |
| Site 113 | “Butte” | “Montana” |
| Site 103 | “Knoxville” | “Tennessee” |
| Site 104 | “Austin” | “Texas” |
| Site 106 | “San Antonio” | “Texas” |
Congress presentation of the results
Study design
Randomized, double-blind, placebo-controlled multicenter design
Registry design and masking
| Design element | Registry entry |
|---|---|
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Triple” |
| Primary purpose | “Treatment” |
Seven-arm randomization with screening and follow-up periods
Phase designation in company documents
Eligibility criteria
Inclusion criteria
Body mass index requirement in company documents
Treatment
Once-daily oral tablet dose arms and titration schedules
Exploratory maintenance cohort: 90 mg induction followed by 30 mg daily
Titration in two-week steps starting at 30 mg
Tablet strength, pill count, and fasting administration
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Primary endpoint: percent change in body weight at week 13
Secondary endpoints: proportions reaching 5% and 10% weight loss
Safety outcomes
Pharmacokinetic outcomes not reported
Clinical relevance of weight reduction cited by the investigators
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed by arm
Description of analysis sets
Efficacy and safety populations
Modified intention-to-treat population in the poster
Statistical models for the primary and key secondary endpoints
Sample size calculation and multiplicity control
No evidence found.
Estimand and handling of missing data
No evidence found.
Results
Participant disposition
Treatment and study discontinuation by dose
| Category | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| Discontinued treatment early, n (%) | “7 (18)” | “8 (20)” | “8 (20)” | “11 (28)” | “10 (25)” | “15 (38)” |
| TEAE leading to treatment discontinuation, n (%) | “5 (13)” | “2 (5)” | “5 (13)” | “7 (18)” | “8 (20)” | “12 (30)” |
| Drug-related TEAE leading to treatment discontinuation, n (%) | “3 (8)” | “1 (3)” | “5 (13)” | “6 (15)” | “8 (20)” | “11 (28)” |
| Discontinued study early, n (%) | “2 (5)” | “4 (10)” | “5 (13)” | “5 (13)” | “3 (8)” | “5 (13)” |
| TEAE leading to study discontinuation, n (%) | “1 (3)” | “0” | “1 (3)” | “0” | “1 (3)” | “0” |
| Drug-related TEAE leading to study discontinuation, n (%) | “1 (3)” | “0” | “1 (3)” | “0” | “1 (3)” | “0” |
Pooled discontinuation rates, VK2735 versus placebo
Distinction between treatment discontinuation and study discontinuation
Reasons for discontinuation
Exploratory maintenance cohort discontinuation
Baseline characteristics
Baseline characteristics by arm, safety population
| Characteristic | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Participants | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” | “(n=40)” |
| Age, mean years | “51” | “54” | “53” | “49” | “52” | “50” |
| Sex, % male:female | “30:70” | “20:80” | “45:55” | “15:85” | “32:68” | “28:72” |
| White, % | “85” | “80” | “73” | “68” | “88” | “83” |
| Non-Hispanic, % | “70” | “78” | “80” | “85” | “75” | “73” |
| Weight, mean kg | “105” | “99” | “103” | “103” | “103” | “102” |
| BMI, mean kg/m2 | “38” | “37” | “35” | “37” | “37” | “37” |
| Prediabetes, % | “53” | “45” | “60” | “38” | “68” | “63” |
Overall population: age, sex, race, and prediabetes definition
Mean baseline body weight by arm, efficacy population
| Arm | Mean baseline body weight |
|---|---|
| Placebo | “105.2 kg” |
| VK2735 15 mg | “99.0 kg” |
| VK2735 30 mg | “102.9 kg” |
| VK2735 60 mg | “102.8 kg” |
| VK2735 90 mg | “103.4 kg” |
| VK2735 120 mg | “101.9 kg” |
| Exploratory maintenance cohort | “102.8 kg” |
Efficacy results
Primary and key secondary endpoints at week 13 by dose
| Measure | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Participants, efficacy population | “(n=40)” | “(n=40)” | “(n=40)” | “(n=38)” | “(n=39)” | “(n=39)” |
| Mean change from baseline body weight, least squares mean | “-1.3 kg” | “-2.2 kg” | “-7.1 kg” | “-8.8 kg” | “-11.5 kg” | “-12.1 kg” |
| Mean percent change from baseline, least squares mean | “-1.3 %” | “-2.3 %” | “-7.0 %” | “-8.7 %” | “-11.1 %” | “-12.2 %” |
| p-value versus baseline | “-” | “0.0057” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| Placebo-adjusted mean percent change from baseline | “-” | “-1.0 %” | “-5.7 %” | “-7.4 %” | “-9.8 %” | “-10.9 %” |
| p-value versus placebo, percent change | “-” | “-” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
| Percent reporting at least 10% weight loss | “5 %” | “8 %” | “35 %” | “40 %” | “59 %” | “80 %” |
| p-value versus placebo, at least 10% weight loss | “-” | “-” | “<0.01” | “0.0017” | “< 0.0001” | “<0.0001” |
Proportions achieving at least 5% and at least 10% weight loss
Time course of weight loss from week 1 through week 13
Exploratory maintenance cohort: weight change after transition from 90 mg to 30 mg
| Measure | Week 3, 90 mg | Week 6, 90 mg | Week 9, 30 mg | Week 13, 30 mg |
|---|---|---|---|---|
| Mean change from baseline body weight, least squares mean | “-5.2 kg” | “-8.1 kg” | “-8.8 kg” | “-9.1kg” |
| Mean percent change from baseline, least squares mean | “-5.1 %” | “-8.1 %” | “-8.8 %” | “-9.2 %” |
| Placebo-adjusted mean percent change from baseline | “-4.3 %” | “-6.7 %” | “-7.6 %” | “-7.9 %” |
| p-value versus placebo | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
Weight change at week 16, three weeks after the last dose
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events by dose
Severity of adverse events
Pooled nausea and vomiting rates, VK2735 versus placebo
Common drug-related gastrointestinal adverse events by dose
| Event, number of participants reporting (%) | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Gastroesophageal reflux disease | “0 (0%)” | “3 (8%)” | “0 (0%)” | “2 (5%)” | “1 (3%)” | “3 (8%)” |
| Nausea, mild | “16 (40%)” | “12 (30%)” | “15 (38%)” | “13 (33%)” | “22 (55%)” | “15 (38%)” |
| Nausea, moderate | “3 (8%)” | “2 (5%)” | “7 (18%)” | “8 (20%)” | “7 (18%)” | “7 (18%)” |
| Nausea, severe | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “2 (5%)” |
| Vomiting | “4 (10%)” | “2 (5%)” | “6 (15%)” | “8 (20%)” | “14 (35%)” | “14 (35%)” |
| Abdominal pain | “1 (3%)” | “1 (3%)” | “2 (5%)” | “1 (3%)” | “1 (3%)” | “2 (5%)” |
| Diarrhea | “5 (13%)” | “2 (5%)” | “3 (8%)” | “6 (15%)” | “6 (15%)” | “10 (25%)” |
| Constipation | “9 (23%)” | “9 (23%)” | “8 (20%)” | “12 (30%)” | “17 (43%)” | “11 (28%)” |
Drug-related gastrointestinal adverse events by severity grade
| Severity | Placebo | VK2735 15 mg | VK2735 30 mg | VK2735 60 mg | VK2735 90 mg | VK2735 120 mg |
|---|---|---|---|---|---|---|
| Any drug-related GI TEAE, mild, grade 1, n (%) | “17 (43)” | “18 (45)” | “16 (40)” | “18 (45)” | “21 (53)” | “18 (45)” |
| Any drug-related GI TEAE, moderate, grade 2, n (%) | “6 (15)” | “6 (15)” | “11 (28)” | “12 (30)” | “13 (33)” | “11 (28)” |
| Any drug-related GI TEAE, severe, grade 3, n (%) | “1 (3)” | “0” | “0” | “0” | “0” | “2 (5)” |
| Nausea, mild/moderate/severe, % of participants | “40/8/0” | “30/5/0” | “38/18/0” | “33/20/0” | “55/18/0” | “38/18/5” |
| Constipation, mild/moderate/severe, % of participants | “13/10/0” | “13/10/0” | “10/10/0” | “20/10/0” | “33/10/0” | “25/3/0” |
| Vomiting, mild/moderate/severe, % of participants | “3/8/0” | “5/0/0” | “8/8/0” | “18/3/0” | “30/5/0” | “15/15/5” |
| Diarrhea, mild/moderate/severe, % of participants | “10/0/3” | “5/0/0” | “8/0/0” | “15/0/0” | “10/5/0” | “15/10/0” |
Time course of gastrointestinal adverse events
Placebo adverse event rates and the company's interpretation
Titration rate and gastrointestinal tolerability
Exploratory maintenance cohort adverse events
Laboratory values, vital signs, and heart rate
No evidence found.
Study limitations
Summary: limitations of the VENTURE-Oral Dosing evidence
Treatment lasted 13 weeks, and about 40 participants were randomized to each of 7 arms (280 in total). The release reports that weight loss showed “no plateau” at 13 weeks, so the maximal effect of each dose is not known from these data; FDA draft guidance asks that phase 2 duration capture “maximal or near-maximal” effects and sets its efficacy benchmark after 1 year of treatment. Week 16 off-treatment values were reported only for placebo and the 30, 60, and 90 mg arms.
Results are available only in company press releases, a sponsor-funded congress poster, a corporate presentation, and investor call transcripts. No peer-reviewed publication was identified, and the registry record has no posted results. Pharmacokinetic results, a stated objective, have not been reported. No document describes the sample size calculation, control of multiplicity, the estimand, or the handling of missing data.
Treatment discontinuation was 18% with placebo and ranged from 20% (15 mg and 30 mg) to 38% (120 mg) across the fixed-dose arms; discontinuation of treatment due to a TEAE was 13% with placebo and 30% with 120 mg. The release describes discontinuation due to adverse events as “low and well-balanced”. Its pooled VK2735 rates (28% for any treatment discontinuation and 20% for discontinuation due to an adverse event) are higher than the totals of the 5 fixed-dose arms in the per-arm tables (52 of 200, 26%, and 34 of 200, 17%); no document states whether the pooled rates include the exploratory maintenance cohort, whose disposition and adverse events are reported only as qualitative statements on the investor call. Efficacy was analyzed in a modified population that required a post-baseline weight, with 38 or 39 participants in the 60, 90, and 120 mg arms.
The fixed-dose arms were titrated in 2-week steps starting at 30 mg, every participant took 4 tablets daily after an overnight fast, and no food-effect study had been done. The doses later chosen for the phase 3 SUNRISE trials (27.5, 35, and 55 mg) were not tested as fixed arms. Nausea was reported by 48% of placebo recipients, and the company noted on its investor call that placebo adverse event rates were higher than in the earlier study. Participants with diabetes were excluded, all 15 sites were in the United States, and most participants were White, non-Hispanic, and female.
The documents differ on some points. The ECO release names the poster's trial the “VENTURE-2 Study” and calls the study “Phase 2a”. A corporate presentation note states “Baseline BMI ≥30 in all subjects” although eligibility allowed a BMI of 27 kg/m2 or higher with a comorbidity. The poster footnote on serious adverse events states “Three participants” and then lists one participant in the 60 mg arm and “1 pt with dehydration and 2 pts with nausea/vomiting” in the 120 mg arm. A third-party transcript of a November 2025 presentation records the maintenance cohort ending at 8.2% weight loss, while the release reports 9.2%. The registry arms are labeled “Dose #1” to “Dose #6” without the doses.
VK2735-102 part 1 subcutaneous maintenance
Objective
Safety, tolerability, and pharmacokinetic objectives with exploratory weight endpoints
Brief summary in the ClinicalTrials.gov record
Evaluation of the transition from weekly to monthly or every-other-week dosing
Location and study date
Initiation in October 2025 and completion of enrollment in January 2026
Top-line results announced in September 2026
Study dates and United States sites in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Study start (actual) | “2025-11-18” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-07” |
| First posted | “2026-09-24” |
| Site 1 | “Viking Clinical Site #001” |
| Site 1 city | “Lake Forest” |
| Site 2 | “Viking Clinical Site #002” |
| Site 2 city | “Miami” |
Study design
Design as reported with the top-line results: 21-week induction and subcutaneous maintenance
Part 1 as one part of a two-part range-finding study
Study periods in the investor presentation
“6-week screening” (opens the source at this quote in a new tab)
“Weekly SC titration (21 weekly doses)” (opens the source at this quote in a new tab)
“12-week maintenance” (opens the source at this quote in a new tab)
“5-week follow-up” (opens the source at this quote in a new tab)
“Part 1: Subcutaneous (SC) maintenance dosing” (opens the source at this quote in a new tab)
Placebo comparator for the maintenance period
Two study parts and 18 treatment groups in the ClinicalTrials.gov record
Design details in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Official title | “A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities” |
| Other study ID | “VK2735-102” |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
| Primary purpose | “Treatment” |
Original design announced at initiation: 19-week induction with oral and subcutaneous maintenance options
Design stated at completion of enrollment: 19-week induction with oral and subcutaneous maintenance options
Design described in the annual report filed in February 2026
Eligibility criteria
Obesity without other comorbidities
Inclusion criteria in the ClinicalTrials.gov record (both study parts)
Exclusion criteria in the ClinicalTrials.gov record (both study parts)
Age range in the ClinicalTrials.gov record
| Field | Registry value |
|---|---|
| Minimum age | “18 Years” |
| Maximum age | “60 Years” |
Treatment
Two-week titration steps to induction doses of 15.0 to 22.5 mg
Monthly maintenance regimens
Part A treatment arms in the ClinicalTrials.gov record
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary and secondary outcome measures
Percentage of week 21 weight loss maintained at week 33
Company view of the weight-loss threshold for cardiometabolic benefit
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment at initiation and enrollment at completion
Estimated enrollment across both parts in the ClinicalTrials.gov record
Participants in the induction safety population and with an observed week 21 weight
Participants analyzed in the maintenance period
| Group | Efficacy population | Safety population |
|---|---|---|
| Placebo after 17.5 mg weekly | “(n=27)” | “(n=27)” |
| VK2735 combined every other week | “(n=37)” | “(n=37)” |
| VK2735 combined monthly | “QM (n=65)” | “QM (n=66)” |
Description of analysis sets
Induction and maintenance safety populations
Statistical methods for weight endpoints
Results
Participant disposition
Discontinuations during the 21-week induction period
Discontinuations during the every-other-week maintenance period
Discontinuations during the monthly maintenance period
| Outcome | Placebo (n=27) | VK2735 combined (n=66) | 10 mg (n=16) | 15 mg (n=14) | 17.5 mg (n=11) | 20 mg (n=14) | 22.5 mg (n=11) |
|---|---|---|---|---|---|---|---|
| Discontinued treatment early | “0 (0 %)” | “3 (5 %)” | “0 (0 %)” | “1 (7 %)” | “1 (9 %)” | “1 (7 %)” | “0 (0 %)” |
| Discontinued treatment due to adverse event | “0 (0 %)” | “1 (2 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (7 %)” | “0 (0 %)” |
Baseline characteristics
Mean baseline body weight by induction dose
| Group | Mean baseline body weight |
|---|---|
| Placebo (n=15) | “100.0 kg” |
| VK2735 15 mg weekly (n=14) | “108.4 kg” |
| VK2735 17.5 mg weekly (n=118) | “95.9 kg” |
| VK2735 20 mg weekly (n=15) | “101.9 kg” |
| VK2735 22.5 mg weekly (n=14) | “103.0 kg” |
Baseline body mass index requirement
Efficacy results
Change in body weight after 21 weeks of weekly dosing
| Measure | Placebo (n=15) | 15 mg weekly (n=14) | 17.5 mg weekly (n=118) | 20 mg weekly (n=15) | 22.5 mg weekly (n=14) |
|---|---|---|---|---|---|
| Mean change from baseline body weight | “-0.1 kg” | “-17.0 kg” | “-17.0 kg” | “-18.6 kg” | “-17.2 kg” |
| Mean percent change from baseline | “-0.1 %” | “-16.3 %” | “-17.8 %” | “-18.7 %” | “-17.1 %” |
| Placebo-adjusted mean percent change from baseline | “-” | “-16.2 %” | “-17.7 %” | “-18.6 %” | “-17.0 %” |
| p-value vs. placebo | “-” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |
Weight-loss thresholds at week 21
Weight loss maintained after transition to every-other-week dosing
Percentage of week 21 weight loss maintained at week 33 with every-other-week dosing
| Measure | Placebo (n=27) | Combined every other week (n=37) | 17.5 mg weekly to 5.0 mg every other week (n=12) | 15.0 mg weekly to 7.5 mg every other week (n=13) | 17.5 mg weekly to 10.0 mg every other week (n=12) |
|---|---|---|---|---|---|
| Mean percentage of week 21 weight loss maintained at week 33 | “61 %” | “90 %” | “83 %” | “90 %” | “97 %” |
| p-value vs. placebo | “-” | “p<0.0001” | “0.004” | “<0.0001” | “<0.0001” |
Weight loss maintained after transition to monthly dosing
Percentage of week 21 weight loss maintained at week 33 with monthly dosing
| Measure | Placebo (n=27) | Combined monthly (n=65) | 17.5 mg weekly to 10 mg monthly (n=16) | 17.5 mg weekly to 15 mg monthly (n=14) | 17.5 mg weekly to 17.5 mg monthly (n=11) | 20 mg weekly to 20 mg monthly (n=14) | 22.5 mg weekly to 22.5 mg monthly (n=10) |
|---|---|---|---|---|---|---|---|
| Mean percentage of week 21 weight loss maintained at week 33 | “61 %” | “85 %” | “82 %” | “84 %” | “90 %” | “86 %” | “85 %” |
| p-value vs. placebo | “-” | “<0.0001” | “0.0016” | “0.0012” | “0.0002” | “0.0005” | “0.0024” |
Continued 17.5 mg weekly dosing through week 33
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events and gastrointestinal adverse events through week 21
| Event | Placebo (n=15) | VK2735 combined (n=166) | 15 mg weekly (n=15) | 17.5 mg weekly (n=121) | 20 mg weekly (n=15) | 22.5 mg weekly (n=15) |
|---|---|---|---|---|---|---|
| Treatment-emergent adverse events | “7 (47%)” | “116 (70%)” | “11 (73%)” | “83 (69%)” | “10 (67%)” | “12 (80%)” |
| Nausea, mild | “1 (7%)” | “67 (40%)” | “6 (40%)” | “47 (39%)” | “3 (20%)” | “11 (73%)” |
| Nausea, moderate | “0 (0%)” | “3 (2%)” | “0 (0%)” | “2 (2%)” | “0 (0%)” | “1 (7%)” |
| Vomiting | “1 (7%)” | “45 (27%)” | “6 (40%)” | “32 (26%)” | “2 (13%)” | “5 (33%)” |
| Diarrhea | “3 (20%)” | “33 (20%)” | “3 (20%)” | “24 (20%)” | “3 (20%)” | “3 (20%)” |
| Constipation | “1 (7%)” | “18 (11%)” | “1 (7%)” | “12 (10%)” | “1 (7%)” | “4 (27%)” |
Tolerability during the maintenance period
Adverse events after transition to every-other-week dosing
| Event | Placebo (n=27) | VK2735 combined (n=37) | 5.0 mg (n=12) | 7.5 mg (n=13) | 10.0 mg (n=12) |
|---|---|---|---|---|---|
| Treatment-emergent adverse events | “14 (52 %)” | “14 (38 %)” | “4 (33 %)” | “5 (39 %)” | “5 (42 %)” |
| Nausea, mild | “0 (0 %)” | “2 (5 %)” | “1 (8 %)” | “1 (8 %)” | “0 (0 %)” |
| Vomiting | “2 (7 %)” | “1 (3 %)” | “0 (0 %)” | “0 (0 %)” | “1 (8 %)” |
| Diarrhea | “1 (4 %)” | “2 (5 %)” | “0 (0 %)” | “2 (15 %)” | “0 (0 %)” |
| Constipation | “1 (4 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |
Adverse events after transition to monthly dosing
| Event | Placebo (n=27) | VK2735 combined (n=66) | 10 mg (n=16) | 15 mg (n=14) | 17.5 mg (n=11) | 20 mg (n=14) | 22.5 mg (n=11) |
|---|---|---|---|---|---|---|---|
| Treatment-emergent adverse events | “14 (52 %)” | “32 (49 %)” | “7 (44 %)” | “7 (50 %)” | “5 (46 %)” | “7 (50 %)” | “6 (55 %)” |
| Nausea, mild | “0 (0 %)” | “3 (4.5 %)” | “1 (6 %)” | “2 (14 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |
| Vomiting | “2 (7 %)” | “5 (8 %)” | “2 (13 %)” | “1 (7 %)” | “1 (9 %)” | “1 (7 %)” | “0 (0 %)” |
| Diarrhea | “1 (4 %)” | “3 (5 %)” | “1 (6 %)” | “0 (0 %)” | “0 (0 %)” | “2 (14 %)” | “0 (0 %)” |
| Constipation | “1 (4 %)” | “2 (3 %)” | “1 (6 %)” | “1 (7 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |
Study limitations
Summary: study limitations
Part 1 of the VK2735-102 study was a phase 1 trial in which 180 otherwise healthy adults with a body mass index of at least 30 kg/m2 and no diabetes were randomized across 11 treatment groups; the registry age range was 18 to 60 years. The primary endpoint was the incidence of treatment-emergent adverse events, and all body weight endpoints were exploratory. The induction placebo group had 15 participants, while 118 of the 176 participants in the induction efficacy population received 17.5 mg weekly. Each maintenance regimen had 10 to 16 participants in the efficacy population, the maintenance period lasted 12 weeks, and the maintenance placebo group (27 participants) consisted of participants switched from 17.5 mg weekly to placebo at week 21. The result for the 22.5 mg monthly cohort excludes one participant with a “maintenance effect >2.5x standard deviation from cohort mean”. During induction, 22 of 166 VK2735-treated participants (13%) discontinued treatment early, including 4 of 15 (27%) at 22.5 mg weekly, compared with 0 of 15 receiving placebo; the induction safety population (181 participants) is 1 larger than the reported number randomized (180). The design changed after initiation: the releases of October 2025 and January 2026 and the Form 10-K of February 2026 described a 19-week induction, maintenance options that included “daily oral doses” and “weekly oral doses”, and an end of study at week 31, whereas the reported Part 1 used a 21-week induction, subcutaneous maintenance only, and an end of study at week 33. The ClinicalTrials.gov record was first posted on 2026-09-24, after enrollment was complete and 2 days after the top-line release, and it lists an estimated enrollment of 270 for both parts. Results are available only in a press release, investor presentations, and a call transcript, with no peer-reviewed publication and no results posted to the registry, and no health-related quality of life outcomes were reported.
Small cohort size acknowledged by the company
Longer extension data preferred for a regulatory submission
VK2735-102 part 2 oral and subcutaneous maintenance
Objective
Oral and additional subcutaneous maintenance regimens after subcutaneous induction
Question the company expects Part 2 to answer
Brief summary in the ClinicalTrials.gov record
Location and study date
Initiation in October 2026
Study dates and United States sites in the ClinicalTrials.gov record (both study parts)
| Field | Registry value |
|---|---|
| Recruitment status | “Recruiting” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-07” |
| Site 1 city | “Lake Forest” |
| Site 2 city | “Miami” |
Study design
Design announced at initiation, including weekly oral doses
Reason given for not including a weekly oral regimen
Part B in the ClinicalTrials.gov record
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record (both study parts)
Exclusion criteria in the ClinicalTrials.gov record (both study parts)
Treatment
Subcutaneous formulation: weekly induction for 21 weeks
Oral formulation: daily maintenance doses up to 55 mg in five arms
Oral formulation: doses named at the top-line call
Subcutaneous formulation: six every-other-week and monthly maintenance arms
Part B treatment arms in the ClinicalTrials.gov record
Interventions in the ClinicalTrials.gov record
| Intervention | Registry description |
|---|---|
| VK2735 | “SC or oral once daily, once weekly, every other week, or monthly” |
| Placebo | “SC or oral once daily or once weekly” |
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary and secondary outcome measures
Body weight as an exploratory endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of approximately 195 participants
Estimated enrollment across both parts in the ClinicalTrials.gov record
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: study limitations
Part 2 of the VK2735-102 study began in October 2026, and no results have been reported; the company expects results in 2027. It is a phase 1 trial in approximately 195 otherwise healthy adults with a body mass index of at least 30 kg/m2, with a 12-week maintenance period after 21 weeks of weekly subcutaneous induction, a primary endpoint of treatment-emergent adverse events, and body weight change as an exploratory endpoint. The documents disagree on the regimens. The initiation release of 6 October 2026 listed “weekly oral doses”, and a correction note issued on 14 October 2026 removed them; the ClinicalTrials.gov record still lists a group receiving VK2735 “orally weekly” and a group receiving placebo “orally once weekly”. The registry describes 6 Part B arms receiving “one of four VK2735 dose regimens or matching placebo regimen”, while the chief executive officer described five oral arms and six subcutaneous arms. The oral doses have not been disclosed; the September 2026 call named 17.5, 27.5, and 55 mg, and the October 2026 call gave a range of about 17 to 55 mg. The registry estimate of 270 participants for both parts is smaller than the sum of the 180 participants randomized in Part 1 and the approximately 195 planned for Part 2.
Uncertain response after the step down from weekly subcutaneous to daily oral dosing
VK2735-101 subcutaneous parts A and B
Objective
Safety, tolerability, and dose identification as primary objectives
Exploratory pharmacodynamic assessments of body weight and liver fat
First administration to humans and nonalcoholic steatohepatitis as the initial target
Study objectives in the ISRCTN record
Location and study date
Single centre in Adelaide, Australia, in the ISRCTN record
| Field | Registry value |
|---|---|
| Countries of recruitment | “Australia” |
| Study participating centre | “Cmax Clinical Research Pty Ltd” |
| Date of first enrolment | “01/12/2021” |
| Date of final enrolment | “01/06/2023” |
| Planned study period | “December 2021 to December 2022” |
Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Study start (actual) | “2021-12-14” |
| Primary completion (actual) | “2024-11-04” |
| Study completion (actual) | “2024-12-03” |
| Site | “Viking Clinical Site” |
| Site city | “Adelaide” |
Results announced in March 2023 and presented at ObesityWeek 2023
Study design
Randomized, double-blind, placebo-controlled single and multiple ascending dose design
Parts A and B and safety review before dose escalation in the ClinicalTrials.gov record
Cohorts and 3:1 randomization in the ISRCTN record
Design details in the ClinicalTrials.gov record
Eligibility criteria
Healthy adults in Part A and adults with a body mass index of at least 30 kg/m2 in Part B
Participants and age range in the ISRCTN record
Key inclusion criteria in the ISRCTN record
Key exclusion criteria in the ISRCTN record
Treatment
Subcutaneous formulation: single ascending doses in Part A
Subcutaneous formulation: once-weekly multiple ascending doses for 4 weeks in Part B
Subcutaneous formulation: weekly dose levels in the multiple ascending dose cohorts
| Cohort | Dose level |
|---|---|
| Cohort 1 | “VK2735 0.5 mg” |
| Cohort 2 | “VK2735 1.5 mg” |
| Cohort 3 | “VK2735 1.5/3/5/5 mg” |
| Cohort 4 | “VK2735 3/5/5/7.5 mg” |
| Cohort 5 | “VK2735 5/5/7.5/10 mg” |
| Escalation in cohort 3 | “Subjects received escalating weekly doses of 1.5 mg, 3.0 mg, 5.0 mg, 5.0 mg.” |
Subcutaneous formulation: arms in the ClinicalTrials.gov record
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary and secondary outcome measures in ClinicalTrials.gov
Primary and key secondary outcome measures in the ISRCTN record
Statistical analysis description
Number of participants (Planned and analyzed)
Target sample size in the ISRCTN record
Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Enrollment (actual) | “92” |
Description of analysis sets
Statistical methods for liver fat
Results
Participant disposition
No discontinuations for gastrointestinal adverse events in the multiple ascending dose cohorts
Baseline characteristics
Efficacy results
Subcutaneous formulation: pharmacokinetics after single doses
Subcutaneous formulation: pharmacokinetic summary in the corporate presentation
Change in body weight by multiple ascending dose cohort at day 28
| Measure | Placebo (n=10) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=7) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=6) |
|---|---|---|---|---|---|---|
| Mean change from baseline body weight | “-2.2 kg” | “-2.6 kg” | “-4.1 kg” | “-4.5 kg” | “-8.2 kg” | “-7.6 kg” |
| Mean percent change from baseline | “-1.8 %” | “-2.5 %” | “-3.7 %” | “-4.1 %” | “-7.4 %” | “-7.8 %” |
| Placebo-adjusted mean change from baseline | “-” | “-0.7 %” | “-1.9 %” | “-2.3 %” | “-5.6 %” | “-6.0 %” |
| p-value vs. placebo | “-” | “0.64” | “0.17” | “0.09” | “0.0003” | “0.0002” |
Durability of weight loss after the last dose
Conclusions of the ObesityWeek 2023 abstract
Liver fat after 28 days of weekly dosing
Change in liver fat content by multiple ascending dose cohort
| Measure | Placebo | 0.5 mg | 1.5 mg | 1.5/3/5/5 mg | 3/5/5/7.5 mg | 5/5/7.5/10 mg |
|---|---|---|---|---|---|---|
| Mean percent change from baseline, all participants | “-0.7” | “3.9” | “-24.2” | “-24.0” | “-47.2” | “-8.4” |
| p-value vs. placebo, all participants | “-” | “0.74” | “0.09” | “0.10” | “0.002” | “0.62” |
| Mean percent change from baseline, nonalcoholic fatty liver disease subset | “8.8” | “-” | “-33.8” | “-32.5” | “-49.7” | “-10.7” |
| p-value vs. placebo, nonalcoholic fatty liver disease subset | “-” | “-” | “0.03” | “0.03” | “0.006” | “-” |
Plasma lipids after 28 days of weekly dosing
Change in plasma lipids by multiple ascending dose cohort
| Measure | Placebo (n=9) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=6) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=4) |
|---|---|---|---|---|---|---|
| Mean change in apolipoprotein B from baseline (%) | “1.8” | “3.3” | “-1.8” | “-12.9” | “-12.5*” | “-20.5” |
| Mean change in LDL-C from baseline (%) | “-9.5” | “1.4” | “-10.6” | “-13.7” | “-20.3*” | “-23.0” |
| Mean change in total cholesterol from baseline (%) | “-5.1” | “-1.7” | “-10.8” | “-14.9*” | “-17.4*” | “-21.0” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Tolerability of single doses
Adverse events after repeated weekly dosing
Commonly reported adverse events by multiple ascending dose cohort
| Event | Placebo (n=10) | 0.5 mg (n=6) | 1.5 mg (n=6) | 1.5/3/5/5 mg (n=7) | 3/5/5/7.5 mg (n=6) | 5/5/7.5/10 mg (n=6) |
|---|---|---|---|---|---|---|
| Nausea, mild | “5 (50%)” | “2 (33%)” | “4 (67%)” | “4 (57%)” | “5 (83%)” | “1 (17%)” |
| Nausea, moderate | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (14%)” | “0 (0%)” | “1 (17%)” |
| Vomiting | “1 (10 %)” | “2 (33 %)” | “0 (0 %)” | “2 (29 %)” | “1 (17 %)” | “1 (17 %)” |
| Diarrhea | “3 (30 %)” | “1 (17 %)” | “1 (17 %)” | “2 (29 %)” | “0 (0 %)” | “0 (0 %)” |
| Constipation | “0 (0 %)” | “1 (17 %)” | “1 (17 %)” | “2 (29 %)” | “1 (17 %)” | “0 (0 %)” |
| Decreased appetite | “3 (30 %)” | “3 (50 %)” | “3 (50 %)” | “4 (57 %)” | “5 (83 %)” | “6 (100 %)” |
Higher doses expected to need longer titration
Study limitations
Summary: study limitations
VK2735-101 Parts A and B were the first administration of VK2735 to humans, conducted at a single centre in Adelaide, Australia, in healthy adults (Part A) and otherwise healthy adults with a body mass index of at least 30 kg/m2 (Part B). The registered primary endpoint was the incidence of treatment-emergent adverse events, and body weight, liver fat, and lipids were exploratory pharmacodynamic measures. The multiple ascending dose part dosed participants once weekly for 4 weeks, with 6 or 7 participants in each VK2735 cohort and 10 receiving placebo, and the highest weekly dose (10 mg) is lower than the doses later carried into phase 2 and phase 3. The liver fat subgroup with nonalcoholic fatty liver disease contained 0 to 4 participants per cohort. Single-dose results by dose level, participant disposition, and baseline characteristics other than body weight and liver fat were not reported. The ISRCTN record named nonalcoholic steatohepatitis as the condition VK2735 was being developed for and a target sample size of 88; the ClinicalTrials.gov record reports an actual enrollment of 92 for Parts A, B, and C combined, whereas the oral first-in-human poster reports that 92 participants were randomized in the oral part alone. The two documents also differ on the time to maximum concentration (approximately 75 to 90 hours in the results release and about 72 hours in the corporate presentation). Results are available only in press releases, a corporate presentation, and a congress abstract, with no peer-reviewed full publication and no results posted to either registry.
Intention to publish date moved in the ISRCTN record
VK2735-101 oral part C
Objective
Oral formulation: safety and tolerability of a once-daily tablet for 28 days
Oral formulation: objectives stated in the poster
Oral formulation: Part C in the ClinicalTrials.gov record
Location and study date
Results through 40 mg in March 2024 and through 100 mg at ObesityWeek 2024
Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Primary completion (actual) | “2024-11-04” |
| Study completion (actual) | “2024-12-03” |
| Site city | “Adelaide” |
Study design
Oral formulation: extension of the subcutaneous phase 1 study
Oral formulation: dose escalation after review of each cohort
Oral formulation: dose escalation continued beyond 40 mg after the interim results
Oral formulation: exploratory daily to every-other-day cohort
Eligibility criteria
Oral formulation: healthy adults with a body mass index of at least 30 kg/m2
Inclusion and exclusion criteria in the ClinicalTrials.gov record (Parts A, B, and C)
Age range in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Minimum age | “18 Years” |
| Maximum age | “65 Years” |
Treatment
Oral formulation: daily and every-other-day regimens at 80 mg
Oral formulation: arms in the ClinicalTrials.gov record
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Oral formulation: safety and tolerability as the primary objective
Registered primary outcome measure (Parts A, B, and C)
Oral formulation: exploratory proportion with at least 5% weight loss
Statistical analysis description
Number of participants (Planned and analyzed)
Oral formulation: participants analyzed by cohort
Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Enrollment (actual) | “92” |
Description of analysis sets
Oral formulation: efficacy and safety populations
Oral formulation: mixed model for repeated measures
Oral formulation: tests for weight change and responder proportions
Results
Participant disposition
Oral formulation: early study discontinuation by cohort
Baseline characteristics
Oral formulation: mean baseline characteristics by cohort
| Group | Age | Sex, M:F (%) | White (%) | Weight (kg) | BMI (kg/m2) |
|---|---|---|---|---|---|
| Placebo (n=19) | “38” | “47:53” | “68” | “99” | “36” |
| VK2735 2.5 mg (n=8) | “34” | “63:37” | “75” | “102” | “36” |
| VK2735 5 mg (n=7) | “29” | “43:57” | “71” | “97” | “34” |
| VK2735 10 mg (n=6) | “35” | “17:83” | “100” | “97” | “36” |
| VK2735 20 mg (n=8) | “35” | “63:37” | “88” | “111” | “36” |
| VK2735 40 mg (n=8) | “33” | “25:75” | “63” | “89” | “33” |
| VK2735 60 mg (n=9) | “44” | “33:67” | “89” | “108” | “37” |
| VK2735 80 mg (n=9) | “44” | “56:44” | “100” | “102” | “35” |
| VK2735 100 mg (n=9) | “44” | “44:56” | “67” | “103” | “35” |
Efficacy results
Oral formulation: weight loss at day 28 through 100 mg
Oral formulation: change in body weight by cohort at day 28
| Measure | Placebo (n=18) | 2.5 mg (n=8) | 5 mg (n=6) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=7) | 60 mg (n=9) | 80 mg (n=9) | 100 mg (n=9) |
|---|---|---|---|---|---|---|---|---|---|
| Mean baseline body weight | “98.3 kg” | “102.3 kg” | “95.3 kg” | “97.1 kg” | “111.3 kg” | “90.0 kg” | “107.7 kg” | “102.0 kg” | “102.7 kg” |
| Mean change from baseline body weight | “-1.4 kg” | “-0.3 kg” | “-0.8 kg” | “-1.3 kg” | “-3.6 kg” | “-4.8 kg” | “-4.4 kg” | “-5.3 kg” | “-8.2 kg” |
| Mean percent change from baseline | “-1.4 %” | “-0.3 %” | “-0.8 %” | “-1.1 %” | “-3.5 %” | “-5.1 %” | “-4.1 %” | “-5.2 %” | “-8.2 %” |
| Placebo-adjusted mean percent change from baseline | “-” | “1.0 %” | “0.6 %” | “0.3 %” | “-2.2 %” | “-3.7 %” | “-2.7 %” | “-3.9 %” | “-6.8 %” |
| p-value vs. placebo | “-” | “-” | “-” | “-” | “0.0174” | “0.0001” | “0.0026” | “<0.0001” | “<0.0001” |
| Percent reporting at least 5% weight loss | “0 %” | “0 %” | “0 %” | “0 %” | “25 %” | “57 %” | “38 %” | “63 %” | “100 %” |
| p-value vs. placebo for at least 5% weight loss | “-” | “-” | “-” | “-” | “0.0933” | “0.0033” | “0.0243” | “0.0011” | “<0.0001” |
Oral formulation: daily to every-other-day transition at 80 mg
Oral formulation: progressive weight loss and durability through day 57
Oral formulation: pharmacokinetic exposure across doses
Oral formulation: satiety and decreased appetite
Oral formulation: summary in the corporate presentation
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Oral formulation: adverse event summary by cohort
| Event | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) |
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment-emergent adverse events | “16 (84%)” | “6 (75%)” | “6 (86%)” | “4 (67%)” | “6 (75%)” | “7 (88%)” | “9 (100%)” | “9 (100%)” | “8 (89%)” | “9 (100%)” |
| Drug-related treatment-emergent adverse events | “11 (58%)” | “4 (50%)” | “4 (57%)” | “3 (50%)” | “4 (50%)” | “7 (88%)” | “6 (67%)” | “9 (100%)” | “7 (78%)” | “9 (100%)” |
| Serious adverse events | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (11%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” |
Oral formulation: gastrointestinal adverse events by cohort
| Event | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) | Combined (n=73) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nausea, mild | “2 (11%)” | “0 (0%)” | “1 (14%)” | “0 (0%)” | “2 (25%)” | “2 (25%)” | “2 (22%)” | “6 (67%)” | “4 (44%)” | “6 (67%)” | “23 (32%)” |
| Vomiting | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “3 (4 %)” |
| Diarrhea | “4 (21 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (13 %)” | “0 (0 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “5 (7 %)” |
| Constipation | “3 (16 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “3 (33 %)” | “2 (22 %)” | “1 (11 %)” | “4 (44 %)” | “10 (14 %)” |
Oral formulation: severity of adverse events through 100 mg
Oral formulation: interim safety through 40 mg
Study limitations
Summary: study limitations
VK2735-101 Part C was the first administration of the oral tablet formulation, in otherwise healthy adults with a body mass index of at least 30 kg/m2 who took VK2735 once daily for 28 days with follow-up to day 57. Safety and tolerability were the primary objectives, and body weight was an exploratory measure. Each VK2735 cohort had 6 to 9 participants and the pooled placebo group had 17 to 19, depending on the analysis; the every-other-day cohort at 80 mg had 9 participants. The tablet doses studied (2.5 to 100 mg) differ from the doses carried into phase 3 (27.5, 35, and 55 mg), and 28 days of dosing does not show where weight loss plateaus. Part C has no registry record of its own: the ClinicalTrials.gov record for NCT05203237 describes Part C in its detailed description but registers a single primary outcome, safety after single subcutaneous doses over 8 days, and reports an actual enrollment of 92 for Parts A, B, and C, the same number the poster reports as randomized in Part C alone. The interim release of March 2024 stated that “no serious adverse events (SAEs) have been reported to date” for cohorts through 40 mg; the poster reports one serious adverse event in the 60 mg cohort (1 of 9, 11%) without describing it. Results are available only in press releases, a corporate presentation, and a congress poster, with no peer-reviewed publication and no results posted to the registry.